ArticleInternational journal of ophthalmology2025
Chinese medicine formula "Qingxuan Runmu Yin" alleviating ocular surface inflammation in a rat model of dry eye disease by modulating the TLR4/TAK1/p38MAPK pathway.
Article in International journal of ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo investigate the effects of a Chinese medicine formula "Qingxuan Runmu Yin" (QRY) on ocular surface inflammation in a rat model of dry eye, and its mechanism
methodsSeventy-two Sprague-Dawley rats were randomly divided into six groups (
resultsCompared to the control group, the model group showed significant reductions in SIT and increases in CFS scores, alongside structural disorganization of corneal/conjunctival tissues, decreased conjunctival goblet cell (CGC) numbers, and elevated expression of inflammatory markers [interleukin (IL)-1β, IL-6, tumor necrosis factor-alpha (TNF-α), matrix metalloproteinase-9 (MMP9)] and pathway proteins (TLR4, p-TAK1, p-p38MAPK;
conclusionQRY may alleviate ocular surface inflammation associated with dry eye by inhibiting the TLR4/TAK1/p38MAPK signaling pathway, highlighting its potential therapeutic efficacy for dry eye.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.